8-KMaterial AgreementsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Nov 25, 2011)

Filed November 25, 2011For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) announced on November 21, 2011, its entry into a definitive Agreement and Plan of Merger to acquire Pharmasset, Inc. This strategic move involves a tender offer for all outstanding Pharmasset common stock at a price of $137.00 per share, in cash. Following the tender offer, Gilead intends to complete a merger, making Pharmasset a wholly-owned subsidiary. The acquisition is expected to significantly bolster Gilead's pipeline, particularly in the area of hepatitis C (HCV) antivirals, as Pharmasset was known for its promising investigational compounds. Investors should note that the transaction is subject to customary closing conditions, including the satisfaction of the Minimum Tender Condition (at least a majority of outstanding shares) and antitrust approvals.

Key Highlights

  • 1Gilead Sciences to acquire Pharmasset, Inc. for $137.00 per share in cash.
  • 2The acquisition is structured as a tender offer followed by a merger.
  • 3Pharmasset is a key player in the development of hepatitis C (HCV) antiviral treatments.
  • 4The deal aims to significantly enhance Gilead's pipeline in the antiviral space.
  • 5The transaction is contingent on a minimum tender of shares, representing at least a majority of Pharmasset's outstanding common stock.
  • 6Antitrust clearance, including under the Hart-Scott-Rodino Act, is a required condition for closing.

Frequently Asked Questions

The primary strategic goal for Gilead Sciences in acquiring Pharmasset is to significantly strengthen its pipeline, particularly in the development of novel treatments for hepatitis C (HCV). Pharmasset possessed promising investigational HCV antiviral drug candidates that are expected to be highly complementary to Gilead's existing portfolio.

Gilead Sciences has agreed to acquire Pharmasset for $137.00 per share, to be paid in cash to Pharmasset stockholders. This price is net of any required withholding taxes.

The transaction is subject to several conditions, including the successful completion of a tender offer where at least a majority of Pharmasset's outstanding shares are tendered and not withdrawn. Additionally, regulatory approvals, such as clearance under the Hart-Scott-Rodino Antitrust Improvements Act, are required. Other customary closing conditions will also apply.

The Form 8-K filing indicates that the tender offer has not yet commenced as of the filing date (November 24, 2011). Gilead is expected to file a Tender Offer Statement on Schedule TO with the SEC once the offer is launched.